Beautiful late trade on ISRG .......twice tested $467ish
AAPL no-brainer of a short above $398 at 10:30AM
GOOG Option low of .55 cents runs UP to nearly $10 !!!
I traded VMW as it touched close to $70 on back of IBM Miss
CF had nice bounce from $170 this week.....
Any other notable trades ??
ALLISON (back from VAC)
.... I dont believe there is ANY bear argument at the moment....
BUT how can stocks & bonds go the SAME Direction ??
Sequester came & went & NO FEAR of Cuts
I did see the "UVXY" spike to $13+ from a $9 LOW two weeks ago !!
As AAPL will OVERSHOOT to the Downside ,the S&P will OVERSHOOT to the UPSIDE ~~~ 1560's
HUGE short-covering RALLY may be the "CLIMACTIC" TOP we hope for !!
Watch the 27th for D-DAY !!!
RCW Dignity Phase II study can be moved forward, but unless earlier line patients are selected, this will not complete enrollment for quite some time, perhaps as late as mid-2014. Even then, moving earlier line is no guarantee, since we have no evidence that ThermoDox works in early line RCW patients (for example, as the first chemo or prior to radiation).
HIFU bone metastases Phase II study with Philips may move forward (and was expected to enroll first patient in early 2013 from prior guidance), but even if this moves forward and shows benefit, HIFU itself still has a huge adoption curve, and the commercial prospects of this indication would be not be realized for quite some time.
LTSL platform is in jeopardy altogether given the above, particularly since we know from recent presentations that improvements are being made very rapidly in terms of other heat sensitive liposomes. For example, we know that while early stage still, some liposomes are being developed that are much more stable than ThermoDox, and release doxorubicin contents more efficiently. The ideal liposome would be 100% stable at body temperature (which ThermoDox is not), and release contents via some form of trigger, be it heat or some other source such as sound. Point is, the platform altogether might be in jeopardy given the aforementioned.
I see bankruptcy in the very near future Celsion, and they would be wise to sell off rights to LTSL docetaxel and carboplatin for whatever they can get for it. HEAT was validation for the entire platform, and that failed miserably. Remember, it is not like they have that much time left from a patent perspective either (2021), and the above mentioned docetaxel and carboplatin LTSL products are still in preclinical stages.
Did they REALLY buy to OPEN a position
Or have they SOLD Shares SHORT ???
I cant tell......
SO what does that mean ??
Analyst Coverage ?
We re-test the LOW of $1.15 ?
Or is it better to wait AFTER the release ??
RVBD & RAX both -20% after Release !!
Somebody has to be taking Market-Share !
are you hinting at possible "reversal" day
Outisde day within candlestick ?
Watch for CRM at 4PM
......Did you catch ANF & ISRG short at the Open ?
ANF popped up to above $30 in pre-market i believe
JOY had nice move down to $62.10 & back up strongly at Close
JOY ,FSLR, CRM ,PCLN & MAKO all report Tues.
Had gotten a total of 7900 shares avg. price of $11.08
all today ONLY
Hoping for another bounce to $12.50 soon.........
look at CLSN & OCLR as other laggards
I cant get those #'s
It seems 1495 is SOLID support for ES-F
And SPY support comes in at 150.72
WHY do you say that ?
there been positive News recently - took it to $12.55 !
ISRG leads the way....